These dietary changes can exacerbate the weight changes after a person stops using a GLP-1 drug
If you experience a suspected adverse reaction to any medicine or substance including unlicensed compounds you can report this to the MHRA via the Yellow Card Scheme at yellowcard.mhra.gov.uk
On September 18th, we hosted an in-depth webinar exploring the role anti-obesity medications like GLP-1 agonists can play in reshaping chronic condition management, specifically within employer-sponsored health plans
doi:10.1053/j.gastro.2007.03.054
IGF-1 is the second signal that drives most of the effects people link to GH muscle protein building, fat metabolism, and tissue repair
The preferential fat loss likely results from glucagon receptor activation, which increases resting energy expenditure and promotes fat oxidation as the primary fuel source, sparing protein catabolism for energy needs